Document ID: chunk:federal_register_of_legislation:F2025N00158:schedule:1
Version: federal_register_of_legislation:F2025N00158
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2426–3185

Schedule 1—Amendments— Additional designated brands effective from 1 August 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

  1  Section 5 (after table item dealing with the brand Largactil of the drug Chlorpromazine in the form Tablet containing chlorpromazine hydrochloride 25 mg)
Insert:
Ciloxan  Ciprofloxacin  Ear drops 3 mg (as hydrochloride) per mL, 5 mL  Application to the Ear

  2  Section 5 (after table item dealing with the brand Depo-Nisolone of the drug Methylprednisolone in the form Injection containing methylprednisolone acetate 40 mg in 1 mL)
Insert:
Metoclopramide HCl Medsurge  Metoclopramide  Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL  Injection